Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia

Surveillance of antimicrobial resistance (AMR) enables monitoring of trends in AMR prevalence. WHO recommends laboratory-based surveillance to obtain actionable AMR data at local or national level. However, laboratory-based surveillance may lead to overestimation of the prevalence of AMR due to bias...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-03, Vol.15 (3), p.e0230489-e0230489
Main Authors: Sugianli, Adhi Kristianto, Ginting, Franciscus, Kusumawati, R Lia, Parwati, Ida, de Jong, Menno D, van Leth, Frank, Schultsz, Constance
Format: Article
Language:English
Subjects:
Ambulatory care facilities
Amikacin
Analysis
Antibacterial agents
Antibiotics
Antimicrobial agents
Antimicrobial resistance
Bias
Biology and Life Sciences
Care and treatment
Ceftriaxone
Confidence intervals
Drug resistance
E coli
Escherichia coli
Gynecology
Health aspects
Hospitals
Internal medicine
Klebsiella
Klebsiella pneumoniae
Laboratories
Malik, Adam
Medicine
Medicine and Health Sciences
Meropenem
Microbial drug resistance
Microbiology
Obstetrics
Patients
Piperacillin
Piperacillin-tazobactam
Pneumonia
Population
Prejudice
Research and Analysis Methods
Setting (Literature)
Studies
Surveillance
Surveillance systems
Tazobactam
Trends
Urinary tract
Urinary tract diseases
Urinary tract infections
Urine
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23
cites cdi_FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23
container_end_page e0230489
container_issue 3
container_start_page e0230489
container_title PloS one
container_volume 15
creator Sugianli, Adhi Kristianto
Ginting, Franciscus
Kusumawati, R Lia
Parwati, Ida
de Jong, Menno D
van Leth, Frank
Schultsz, Constance
description Surveillance of antimicrobial resistance (AMR) enables monitoring of trends in AMR prevalence. WHO recommends laboratory-based surveillance to obtain actionable AMR data at local or national level. However, laboratory-based surveillance may lead to overestimation of the prevalence of AMR due to bias. The objective of this study is to assess the difference in resistance prevalence between laboratory-based and population-based surveillance (PBS) among uropathogens in Indonesia. We included all urine samples submitted to the laboratory growing Escherichia coli and Klebsiella pneumoniae in the laboratory-based surveillance. Population-based surveillance data were collected in a cross-sectional survey of AMR in E. coli and K. pneumoniae isolated from urine samples among consecutive patients with symptoms of UTI, attending outpatient clinics and hospital wards. Data were collected between 1 April 2014 until 31 May 2015. The difference in percentage resistance (95% confidence intervals) between laboratory- and population-based surveillance was calculated for relevant antibiotics. A difference larger than +/- 5 percent points was defined as a biased result, precluding laboratory-based surveillance for guiding empirical treatment. We observed high prevalence of AMR ranging between 63.1% (piperacillin-tazobactam) and 85% (ceftriaxone) in laboratory-based surveillance and 41.3% (piperacillin-tazobactam) and 74.2% (ceftriaxone) in population-based surveillance, except for amikacin and meropenem (5.7%/9.8%; 10.8%/5.9%; [laboratory-/population-based surveillance], respectively). Laboratory-based surveillance yielded significantly higher AMR prevalence estimates than population-based surveillance. This difference was much larger when comparing surveillance data from outpatients than from inpatients. All point estimates of the difference between the two surveillance systems were larger than 5 percent points, except for amikacin and meropenem. Laboratory-based AMR surveillance of uropathogens, is not adequate to guide empirical treatment for community-based settings in Indonesia.
doi_str_mv 10.1371/journal.pone.0230489
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2384476612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A618978042</galeid><doaj_id>oai_doaj_org_article_ae6ecdaa05c7482bbf24bbb4039f4fe5</doaj_id><sourcerecordid>A618978042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23</originalsourceid><addsrcrecordid>eNqNk9tq3DAQhk1padK0b1BaQ6G0F7vVyZZ9Uwihh4VAoKdbMZZHGwXbciQ5NK_TJ62cdUK25KL4wmLmm380M5ose0nJmnJJP1y4yQ_QrUc34JowTkRVP8oOac3ZqmSEP753PsiehXBBSMGrsnyaHXDGWEl4dZj9OYXGeYjOX68aCNjmV-jDFPLRjVMH0bphsYfJX6HtOhg05s7kMETbW-1dY6HLPQYb4o0vutwOxvk-x3603urkjh4h9jjEPDmSVBhRxyQ6eTuAv05-0HEOS-aUMp3yzdCmyoKF59kTA13AF8v_KPv5-dOPk6-r07Mvm5Pj05UuaxZXALKoK1ZwMFI0RtatSPWCZKZE09amkAJbglCgREE1CmZ0QWWJvK2MRMaPstc73bFzQS3tDYrxSghZlnQmNjuidXChRm_7dHflwKobg_NbBT5a3aECLFG3AKTQUlSsaQwTTdMIwmsjDBZJ6-OSbWp6bHXqjYduT3TfM9hztXVXSlJSUFomgXeLgHeXE4aoehs0zgNCN-3uXQlGqznXm3_Qh6tbqC2kAuYRzlOZRdVxSataVkTM1PoBKn0tpteQJmZssu8FvN8LSEzE33ELUwhq8_3b_7Nnv_bZt_fYc4QungfXTfP7Cfug2IHprYbg0dw1mRI1r9JtN9S8SmpZpRT26v6A7oJud4f_BSwRH1I</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2384476612</pqid></control><display><type>article</type><title>Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Sugianli, Adhi Kristianto ; Ginting, Franciscus ; Kusumawati, R Lia ; Parwati, Ida ; de Jong, Menno D ; van Leth, Frank ; Schultsz, Constance</creator><contributor>Smyth, Davida S.</contributor><creatorcontrib>Sugianli, Adhi Kristianto ; Ginting, Franciscus ; Kusumawati, R Lia ; Parwati, Ida ; de Jong, Menno D ; van Leth, Frank ; Schultsz, Constance ; Smyth, Davida S.</creatorcontrib><description>Surveillance of antimicrobial resistance (AMR) enables monitoring of trends in AMR prevalence. WHO recommends laboratory-based surveillance to obtain actionable AMR data at local or national level. However, laboratory-based surveillance may lead to overestimation of the prevalence of AMR due to bias. The objective of this study is to assess the difference in resistance prevalence between laboratory-based and population-based surveillance (PBS) among uropathogens in Indonesia. We included all urine samples submitted to the laboratory growing Escherichia coli and Klebsiella pneumoniae in the laboratory-based surveillance. Population-based surveillance data were collected in a cross-sectional survey of AMR in E. coli and K. pneumoniae isolated from urine samples among consecutive patients with symptoms of UTI, attending outpatient clinics and hospital wards. Data were collected between 1 April 2014 until 31 May 2015. The difference in percentage resistance (95% confidence intervals) between laboratory- and population-based surveillance was calculated for relevant antibiotics. A difference larger than +/- 5 percent points was defined as a biased result, precluding laboratory-based surveillance for guiding empirical treatment. We observed high prevalence of AMR ranging between 63.1% (piperacillin-tazobactam) and 85% (ceftriaxone) in laboratory-based surveillance and 41.3% (piperacillin-tazobactam) and 74.2% (ceftriaxone) in population-based surveillance, except for amikacin and meropenem (5.7%/9.8%; 10.8%/5.9%; [laboratory-/population-based surveillance], respectively). Laboratory-based surveillance yielded significantly higher AMR prevalence estimates than population-based surveillance. This difference was much larger when comparing surveillance data from outpatients than from inpatients. All point estimates of the difference between the two surveillance systems were larger than 5 percent points, except for amikacin and meropenem. Laboratory-based AMR surveillance of uropathogens, is not adequate to guide empirical treatment for community-based settings in Indonesia.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0230489</identifier><identifier>PMID: 32226038</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Ambulatory care facilities ; Amikacin ; Analysis ; Antibacterial agents ; Antibiotics ; Antimicrobial agents ; Antimicrobial resistance ; Bias ; Biology and Life Sciences ; Care and treatment ; Ceftriaxone ; Confidence intervals ; Drug resistance ; E coli ; Escherichia coli ; Gynecology ; Health aspects ; Hospitals ; Internal medicine ; Klebsiella ; Klebsiella pneumoniae ; Laboratories ; Malik, Adam ; Medicine ; Medicine and Health Sciences ; Meropenem ; Microbial drug resistance ; Microbiology ; Obstetrics ; Patients ; Piperacillin ; Piperacillin-tazobactam ; Pneumonia ; Population ; Prejudice ; Research and Analysis Methods ; Setting (Literature) ; Studies ; Surveillance ; Surveillance systems ; Tazobactam ; Trends ; Urinary tract ; Urinary tract diseases ; Urinary tract infections ; Urine ; Urogenital system</subject><ispartof>PloS one, 2020-03, Vol.15 (3), p.e0230489-e0230489</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Sugianli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Sugianli et al 2020 Sugianli et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23</citedby><cites>FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23</cites><orcidid>0000-0002-2898-6719 ; 0000-0002-5490-8968 ; 0000-0003-2280-7844</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2384476612/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2384476612?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,25783,27957,27958,37047,37048,44625,53827,53829,75483</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32226038$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Smyth, Davida S.</contributor><creatorcontrib>Sugianli, Adhi Kristianto</creatorcontrib><creatorcontrib>Ginting, Franciscus</creatorcontrib><creatorcontrib>Kusumawati, R Lia</creatorcontrib><creatorcontrib>Parwati, Ida</creatorcontrib><creatorcontrib>de Jong, Menno D</creatorcontrib><creatorcontrib>van Leth, Frank</creatorcontrib><creatorcontrib>Schultsz, Constance</creatorcontrib><title>Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Surveillance of antimicrobial resistance (AMR) enables monitoring of trends in AMR prevalence. WHO recommends laboratory-based surveillance to obtain actionable AMR data at local or national level. However, laboratory-based surveillance may lead to overestimation of the prevalence of AMR due to bias. The objective of this study is to assess the difference in resistance prevalence between laboratory-based and population-based surveillance (PBS) among uropathogens in Indonesia. We included all urine samples submitted to the laboratory growing Escherichia coli and Klebsiella pneumoniae in the laboratory-based surveillance. Population-based surveillance data were collected in a cross-sectional survey of AMR in E. coli and K. pneumoniae isolated from urine samples among consecutive patients with symptoms of UTI, attending outpatient clinics and hospital wards. Data were collected between 1 April 2014 until 31 May 2015. The difference in percentage resistance (95% confidence intervals) between laboratory- and population-based surveillance was calculated for relevant antibiotics. A difference larger than +/- 5 percent points was defined as a biased result, precluding laboratory-based surveillance for guiding empirical treatment. We observed high prevalence of AMR ranging between 63.1% (piperacillin-tazobactam) and 85% (ceftriaxone) in laboratory-based surveillance and 41.3% (piperacillin-tazobactam) and 74.2% (ceftriaxone) in population-based surveillance, except for amikacin and meropenem (5.7%/9.8%; 10.8%/5.9%; [laboratory-/population-based surveillance], respectively). Laboratory-based surveillance yielded significantly higher AMR prevalence estimates than population-based surveillance. This difference was much larger when comparing surveillance data from outpatients than from inpatients. All point estimates of the difference between the two surveillance systems were larger than 5 percent points, except for amikacin and meropenem. Laboratory-based AMR surveillance of uropathogens, is not adequate to guide empirical treatment for community-based settings in Indonesia.</description><subject>Ambulatory care facilities</subject><subject>Amikacin</subject><subject>Analysis</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antimicrobial resistance</subject><subject>Bias</subject><subject>Biology and Life Sciences</subject><subject>Care and treatment</subject><subject>Ceftriaxone</subject><subject>Confidence intervals</subject><subject>Drug resistance</subject><subject>E coli</subject><subject>Escherichia coli</subject><subject>Gynecology</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Internal medicine</subject><subject>Klebsiella</subject><subject>Klebsiella pneumoniae</subject><subject>Laboratories</subject><subject>Malik, Adam</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Meropenem</subject><subject>Microbial drug resistance</subject><subject>Microbiology</subject><subject>Obstetrics</subject><subject>Patients</subject><subject>Piperacillin</subject><subject>Piperacillin-tazobactam</subject><subject>Pneumonia</subject><subject>Population</subject><subject>Prejudice</subject><subject>Research and Analysis Methods</subject><subject>Setting (Literature)</subject><subject>Studies</subject><subject>Surveillance</subject><subject>Surveillance systems</subject><subject>Tazobactam</subject><subject>Trends</subject><subject>Urinary tract</subject><subject>Urinary tract diseases</subject><subject>Urinary tract infections</subject><subject>Urine</subject><subject>Urogenital system</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tq3DAQhk1padK0b1BaQ6G0F7vVyZZ9Uwihh4VAoKdbMZZHGwXbciQ5NK_TJ62cdUK25KL4wmLmm380M5ose0nJmnJJP1y4yQ_QrUc34JowTkRVP8oOac3ZqmSEP753PsiehXBBSMGrsnyaHXDGWEl4dZj9OYXGeYjOX68aCNjmV-jDFPLRjVMH0bphsYfJX6HtOhg05s7kMETbW-1dY6HLPQYb4o0vutwOxvk-x3603urkjh4h9jjEPDmSVBhRxyQ6eTuAv05-0HEOS-aUMp3yzdCmyoKF59kTA13AF8v_KPv5-dOPk6-r07Mvm5Pj05UuaxZXALKoK1ZwMFI0RtatSPWCZKZE09amkAJbglCgREE1CmZ0QWWJvK2MRMaPstc73bFzQS3tDYrxSghZlnQmNjuidXChRm_7dHflwKobg_NbBT5a3aECLFG3AKTQUlSsaQwTTdMIwmsjDBZJ6-OSbWp6bHXqjYduT3TfM9hztXVXSlJSUFomgXeLgHeXE4aoehs0zgNCN-3uXQlGqznXm3_Qh6tbqC2kAuYRzlOZRdVxSataVkTM1PoBKn0tpteQJmZssu8FvN8LSEzE33ELUwhq8_3b_7Nnv_bZt_fYc4QungfXTfP7Cfug2IHprYbg0dw1mRI1r9JtN9S8SmpZpRT26v6A7oJud4f_BSwRH1I</recordid><startdate>20200330</startdate><enddate>20200330</enddate><creator>Sugianli, Adhi Kristianto</creator><creator>Ginting, Franciscus</creator><creator>Kusumawati, R Lia</creator><creator>Parwati, Ida</creator><creator>de Jong, Menno D</creator><creator>van Leth, Frank</creator><creator>Schultsz, Constance</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2898-6719</orcidid><orcidid>https://orcid.org/0000-0002-5490-8968</orcidid><orcidid>https://orcid.org/0000-0003-2280-7844</orcidid></search><sort><creationdate>20200330</creationdate><title>Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia</title><author>Sugianli, Adhi Kristianto ; Ginting, Franciscus ; Kusumawati, R Lia ; Parwati, Ida ; de Jong, Menno D ; van Leth, Frank ; Schultsz, Constance</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Ambulatory care facilities</topic><topic>Amikacin</topic><topic>Analysis</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antimicrobial resistance</topic><topic>Bias</topic><topic>Biology and Life Sciences</topic><topic>Care and treatment</topic><topic>Ceftriaxone</topic><topic>Confidence intervals</topic><topic>Drug resistance</topic><topic>E coli</topic><topic>Escherichia coli</topic><topic>Gynecology</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Internal medicine</topic><topic>Klebsiella</topic><topic>Klebsiella pneumoniae</topic><topic>Laboratories</topic><topic>Malik, Adam</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Meropenem</topic><topic>Microbial drug resistance</topic><topic>Microbiology</topic><topic>Obstetrics</topic><topic>Patients</topic><topic>Piperacillin</topic><topic>Piperacillin-tazobactam</topic><topic>Pneumonia</topic><topic>Population</topic><topic>Prejudice</topic><topic>Research and Analysis Methods</topic><topic>Setting (Literature)</topic><topic>Studies</topic><topic>Surveillance</topic><topic>Surveillance systems</topic><topic>Tazobactam</topic><topic>Trends</topic><topic>Urinary tract</topic><topic>Urinary tract diseases</topic><topic>Urinary tract infections</topic><topic>Urine</topic><topic>Urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sugianli, Adhi Kristianto</creatorcontrib><creatorcontrib>Ginting, Franciscus</creatorcontrib><creatorcontrib>Kusumawati, R Lia</creatorcontrib><creatorcontrib>Parwati, Ida</creatorcontrib><creatorcontrib>de Jong, Menno D</creatorcontrib><creatorcontrib>van Leth, Frank</creatorcontrib><creatorcontrib>Schultsz, Constance</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>Biological Sciences</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sugianli, Adhi Kristianto</au><au>Ginting, Franciscus</au><au>Kusumawati, R Lia</au><au>Parwati, Ida</au><au>de Jong, Menno D</au><au>van Leth, Frank</au><au>Schultsz, Constance</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-03-30</date><risdate>2020</risdate><volume>15</volume><issue>3</issue><spage>e0230489</spage><epage>e0230489</epage><pages>e0230489-e0230489</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><notes>Competing Interests: The authors have declared that no competing interests exist.</notes><abstract>Surveillance of antimicrobial resistance (AMR) enables monitoring of trends in AMR prevalence. WHO recommends laboratory-based surveillance to obtain actionable AMR data at local or national level. However, laboratory-based surveillance may lead to overestimation of the prevalence of AMR due to bias. The objective of this study is to assess the difference in resistance prevalence between laboratory-based and population-based surveillance (PBS) among uropathogens in Indonesia. We included all urine samples submitted to the laboratory growing Escherichia coli and Klebsiella pneumoniae in the laboratory-based surveillance. Population-based surveillance data were collected in a cross-sectional survey of AMR in E. coli and K. pneumoniae isolated from urine samples among consecutive patients with symptoms of UTI, attending outpatient clinics and hospital wards. Data were collected between 1 April 2014 until 31 May 2015. The difference in percentage resistance (95% confidence intervals) between laboratory- and population-based surveillance was calculated for relevant antibiotics. A difference larger than +/- 5 percent points was defined as a biased result, precluding laboratory-based surveillance for guiding empirical treatment. We observed high prevalence of AMR ranging between 63.1% (piperacillin-tazobactam) and 85% (ceftriaxone) in laboratory-based surveillance and 41.3% (piperacillin-tazobactam) and 74.2% (ceftriaxone) in population-based surveillance, except for amikacin and meropenem (5.7%/9.8%; 10.8%/5.9%; [laboratory-/population-based surveillance], respectively). Laboratory-based surveillance yielded significantly higher AMR prevalence estimates than population-based surveillance. This difference was much larger when comparing surveillance data from outpatients than from inpatients. All point estimates of the difference between the two surveillance systems were larger than 5 percent points, except for amikacin and meropenem. Laboratory-based AMR surveillance of uropathogens, is not adequate to guide empirical treatment for community-based settings in Indonesia.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>32226038</pmid><doi>10.1371/journal.pone.0230489</doi><tpages>e0230489</tpages><orcidid>https://orcid.org/0000-0002-2898-6719</orcidid><orcidid>https://orcid.org/0000-0002-5490-8968</orcidid><orcidid>https://orcid.org/0000-0003-2280-7844</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2020-03, Vol.15 (3), p.e0230489-e0230489
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2384476612
source Open Access: PubMed Central; Publicly Available Content Database
subjects Ambulatory care facilities
Amikacin
Analysis
Antibacterial agents
Antibiotics
Antimicrobial agents
Antimicrobial resistance
Bias
Biology and Life Sciences
Care and treatment
Ceftriaxone
Confidence intervals
Drug resistance
E coli
Escherichia coli
Gynecology
Health aspects
Hospitals
Internal medicine
Klebsiella
Klebsiella pneumoniae
Laboratories
Malik, Adam
Medicine
Medicine and Health Sciences
Meropenem
Microbial drug resistance
Microbiology
Obstetrics
Patients
Piperacillin
Piperacillin-tazobactam
Pneumonia
Population
Prejudice
Research and Analysis Methods
Setting (Literature)
Studies
Surveillance
Surveillance systems
Tazobactam
Trends
Urinary tract
Urinary tract diseases
Urinary tract infections
Urine
Urogenital system
title Laboratory-based versus population-based surveillance of antimicrobial resistance to inform empirical treatment for suspected urinary tract infection in Indonesia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T20%3A11%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Laboratory-based%20versus%20population-based%20surveillance%20of%20antimicrobial%20resistance%20to%20inform%20empirical%20treatment%20for%20suspected%20urinary%20tract%20infection%20in%20Indonesia&rft.jtitle=PloS%20one&rft.au=Sugianli,%20Adhi%20Kristianto&rft.date=2020-03-30&rft.volume=15&rft.issue=3&rft.spage=e0230489&rft.epage=e0230489&rft.pages=e0230489-e0230489&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0230489&rft_dat=%3Cgale_plos_%3EA618978042%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c692t-aa7598253af74bf79d4053a72f6efd9f574ed0ea5e7e41ce42fc5176e3d8f7e23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2384476612&rft_id=info:pmid/32226038&rft_galeid=A618978042&rfr_iscdi=true